サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1751198

ソマトスタチン類似体の市場規模、シェア、動向分析レポート：タイプ別、用途別、最終用途別、地域別、セグメント予測、2025年～2030年

Somatostatin Analogs Market Size, Share & Trends Analysis Report By Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, NET), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 90 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
ソマトスタチン類似体の市場規模、シェア、動向分析レポート：タイプ別、用途別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年05月15日
発行: Grand View Research
ページ情報: 英文 90 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ソマトスタチン類似体市場の成長と動向：

Grand View Research社の最新レポートによると、世界のソマトスタチン類似体市場規模は2030年までに111億米ドルに達し、2025年から2030年までのCAGRは13.3％で拡大すると予測されています。

先端巨大症や神経内分泌腫瘍などの疾患に対する認識の高まりが、重要なインパクトのレンダリングドライバーになると予想されています。

先端巨大症は、しばしば下垂体腺腫に起因する過剰な成長ホルモン産生によって引き起こされる慢性内分泌疾患です。2023年には、世界で100万人当たり約4,600人が先端巨大症に罹患し、100万人当たり年間116.9人が新たに診断されたと推定され、この数は増加し続けています。この疾患は通常、男性では40歳前後、女性では45歳前後で診断されるが、人生の3年目から発症することも多いです。したがって、先端巨大症の有病率の増加がソマトスタチン類似体市場を牽引しています。

韓国、日本、インドなどの国々におけるNET診断率の上昇と一人当たり所得の増加は、市場の重要な促進要因です。加えて、製薬会社からの投資が増加していることも、有利な成長機会を生み出すと予想されます。様々な病気に関する関連情報を提供する様々なオンラインポータルサイトが存在することで、人々の意識が高まると予想されます。例えば、Neuroendocrine Cancer Awareness Networkは、症状、利用可能な治療オプション、疾患管理に関連するすべての情報を提供しています。

ソマトスタチン類似体市場のハイライト

  • タイプ別では、オクトレオチドがソマトスタチン類似体市場を独占し、2024年の売上高シェアは36.3%でした。
  • パシレオチドセグメントは予測期間中最も速いCAGRで成長すると予測されます。
  • 用途別では、NET分野が2024年に最大の収益シェアを占め、ソマトスタチン類似体市場を独占し、予測期間中に最も速いCAGRで成長する見込みです。
  • 病院がソマトスタチン類似体市場をリードし、2024年に最大の収益シェアを占めました。
  • 2024年には病院が市場を独占し、診療所セグメントは予測期間中14.4%のCAGRで最速の成長が見込まれます。
  • 北米は、同地域の主要プレイヤーの存在により、世界市場を独占しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ソマトスタチン類似体市場の変数、動向、および範囲

  • 市場系統の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析

第4章 ソマトスタチン類似体市場：タイプ別ビジネス分析

  • タイプ別市場シェア、2024年と2030年
  • タイプ別セグメントダッシュボード
  • 市場規模、予測、動向分析（タイプ別、2018～2030年）
  • オクトレオチド
  • ランレオチド
  • パシレオチド
  • その他

第5章 ソマトスタチン類似体市場：用途別ビジネス分析

  • 用途別市場シェア、2024年および2030年
  • 用途別セグメントダッシュボード
  • 市場規模、予測、動向分析（用途別、2018～2030年）
  • 先端巨大症
  • NET
  • その他

第6章 ソマトスタチン類似体市場：最終用途別ビジネス分析

  • 最終用途別市場シェア、2024年および2030年
  • 最終用途別セグメントダッシュボード
  • 市場規模、予測、動向分析（最終用途別、2018～2030年）
  • 病院
  • クリニック
  • その他

第7章 ソマトスタチン類似体市場：地域別推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域別市場ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年まで：
  • 北米
    • 国別、2018年～2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018年～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
    • ロシア
  • アジア太平洋
    • 国別、2018年～2030年
    • インド
    • 中国
    • 韓国
    • 香港
    • オーストラリア
    • シンガポール
    • 日本
    • タイ
  • ラテンアメリカ
    • 国別、2018年～2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018年～2030年
    • クウェート
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦

第8章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/リスト
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Eli Lilly and Company
    • Medical Device Business Services, Inc.
    • Johnson &Johnson Services, Inc.
    • Stryker
    • Ultragenyx Pharmaceutical Inc.
    • Alexion Pharmaceuticals, Inc.
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global somatostatin analogs market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 5. Global somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 6. Global somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 7. North America somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 9. North America somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 10. North America somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 11. U.S. somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 12. U.S. somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 13. U.S. somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 14. Canada somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 15. Canada somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 16. Canada somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 17. Mexico somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 18. Mexico somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 19. Mexico somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 20. Europe somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 21. Europe somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 22. Europe somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 23. Europe somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 24. UK somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 25. UK somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 26. UK somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 27. Germany somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 28. Germany somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 29. Germany somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 30. France somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 31. France somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 32. France somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 33. Italy somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 34. Italy somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 35. Italy somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 36. Spain somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 37. Spain somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 38. Spain somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 39. Denmark somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 40. Denmark somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 41. Denmark somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 42. Sweden somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 43. Sweden somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 44. Sweden somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 45. Norway somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 46. Norway somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 47. Norway somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 48. Russia somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 49. Russia somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 50. Russia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 52. Asia Pacific somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 53. Asia Pacific somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 54. Asia Pacific somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 55. India somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 56. India somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 57. India somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 58. China somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 59. China somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 60. China somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 61. South Korea somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 62. South Korea somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 63. South Korea somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 64. Hong Kong somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 65. Hong Kong somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 66. Hong Kong somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 67. Australia somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 68. Australia somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 69. Australia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 70. Singapore somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 71. Singapore somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 72. Singapore somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 73. Japan somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 74. Japan somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 75. Japan somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 76. Thailand somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 77. Thailand somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 78. Thailand somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 79. Latin America somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 80. Latin America somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 81. Latin America somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 82. Latin America somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 83. Brazil somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 84. Brazil somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 85. Brazil somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 86. Argentina somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 87. Argentina somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 88. Argentina somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 89. Middle East & Africa somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 90. Middle East & Africa somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 91. Middle East & Africa somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 92. Middle East & Africa somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 93. Kuwait somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 94. Kuwait somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 95. Kuwait somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 96. Saudi Arabia somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 97. Saudi Arabia somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 98. Saudi Arabia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 99. South Africa somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 100. South Africa somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 101. South Africa somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 102. UAE somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 103. UAE somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 104. UAE somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Somatostatin analogs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Type outlook (USD Million)
  • Fig. 10 Application outlook (USD Million)
  • Fig. 11 End Use outlook (USD Million)
  • Fig. 12 Competitive landscape
  • Fig. 13 Somatostatin analogs market dynamics
  • Fig. 14 Somatostatin analogs market: Porter's five forces analysis
  • Fig. 15 Somatostatin analogs market: Pestle analysis
  • Fig. 16 Somatostatin analogs market: Type segment dashboard
  • Fig. 17 Somatostatin analogs market: Type market share analysis, 2024 & 2030
  • Fig. 18 Octreotide market, 2018 - 2030 (USD Million)
  • Fig. 19 Lanreotide market, 2018 - 2030 (USD Million)
  • Fig. 20 Pasireotide market, 2018 - 2030 (USD Million)
  • Fig. 21 Others market, 2018 - 2030 (USD Million)
  • Fig. 22 Somatostatin analogs market: Application segment dashboard
  • Fig. 23 Somatostatin analogs market: Application market share analysis, 2024 & 2030
  • Fig. 24 Somatostatin analogs market, in Acromegaly, 2018 - 2030 (USD Million)
  • Fig. 25 Somatostatin analogs market, in NET, 2018 - 2030 (USD Million)
  • Fig. 26 Somatostatin analogs market, in Others, 2018 - 2030 (USD Million)
  • Fig. 27 Somatostatin analogs market: End Use segment dashboard
  • Fig. 28 Somatostatin analogs market: End Use market share analysis, 2024 & 2030
  • Fig. 29 Hospitals segment market, 2018 - 2030 (USD Million)
  • Fig. 30 Clinics segment market, 2018 - 2030 (USD Million)
  • Fig. 31 Others segment market, 2018 - 2030 (USD Million)
  • Fig. 32 Somatostatin analogs market revenue, by region
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. country dynamics
  • Fig. 37 U.S. somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada country dynamics
  • Fig. 39 Canada somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico country dynamics
  • Fig. 41 Mexico somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 43 UK country dynamics
  • Fig. 44 UK somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 45 Germany country dynamics
  • Fig. 46 Germany somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 47 France country dynamics
  • Fig. 48 France somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy country dynamics
  • Fig. 50 Italy somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain country dynamics
  • Fig. 52 Spain somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 55 Sweden country dynamics
  • Fig. 56 Sweden somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 57 Norway country dynamics
  • Fig. 58 Norway somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 59 Russia country dynamics
  • Fig. 60 Russia somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 62 India country dynamics
  • Fig. 63 India somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 64 China country dynamics
  • Fig. 65 China somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 68 Hong Kong country dynamics
  • Fig. 69 Hong Kong somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 70 Australia country dynamics
  • Fig. 71 Australia somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 72 Singapore country dynamics
  • Fig. 73 Singapore somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 74 Japan country dynamics
  • Fig. 75 Japan somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 76 Thailand country dynamics
  • Fig. 77 Thailand somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil country dynamics
  • Fig. 80 Brazil somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina country dynamics
  • Fig. 82 Argentina somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East & Africa somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa country dynamics
  • Fig. 85 South Africa somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 86 Kuwait country dynamics
  • Fig. 87 Kuwait somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia country dynamics
  • Fig. 89 Saudi Arabia somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 90 South Africa country dynamics
  • Fig. 91 South Africa somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 92 UAE country dynamics
  • Fig. 93 UAE somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 94 Company categorization
  • Fig. 95 Company market position analysis
  • Fig. 96 Strategic framework
目次
Product Code: GVR-3-68038-789-6

Somatostatin Analogs Market Growth & Trends:

The global somatostatin analogs market size is anticipated to reach USD 11.1 billion by 2030 and expand at a CAGR of 13.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing awareness of diseases such as acromegaly and neuroendocrine tumors is expected to be the vital impact rendering driver.

Acromegaly is a chronic endocrine condition caused by excessive growth hormone production, often due to a pituitary adenoma. In 2023, approximately 4,600 people per million globally were affected by acromegaly, with an estimated 116.9 new cases diagnosed annually per million, a number that continues to rise. The disorder is usually diagnosed around age 40 in men and 45 in women, though it often begins in the third decade of life. Hence, the increasing prevalence of acromegaly drives the somatostatin analogs market.

The growing rate of NET diagnoses in countries such as South Korea, Japan, and India and increasing per capita income are significant market drivers. In addition, rising investments from pharmaceutical companies are expected to create lucrative growth opportunities. Existence of different online portals providing related information on various diseases is anticipated to create awareness among the population. For instance, Neuroendocrine Cancer Awareness Network provides all the information related to their symptoms, available treatment options and disease management.

Somatostatin Analogs Market Highlights

  • By type, octreotide dominated the somatostatin analogs market, with a revenue share of 36.3% in 2024.
  • The pasireotide segment is expected to grow at the fastest CAGR over the forecast period.
  • By application, the NET segment dominated the somatostatin analogs market with the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period.
  • Hospitals led the somatostatin analogs market, accounting for the largest revenue share in 2024.
  • Hospitals dominated the market in 2024, and the clinics segment is expected to grow at the fastest CAGR of 14.4% over the forecast period.
  • North America dominated the global market owing to the presence of key players in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Somatostatin Analogs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Somatostatin Analogs Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Octreotide
    • 4.4.1. Octreotide Market, 2018 - 2030 (USD Million)
  • 4.5. Lanreotide
    • 4.5.1. Lanreotide Market, 2018 - 2030 (USD Million)
  • 4.6. Pasireotide
    • 4.6.1. Pasireotide Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Segment Market, 2018 - 2030 (USD Million)

Chapter 5. Somatostatin Analogs Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Acromegaly
    • 5.4.1. Somatostatin Analogs Market, in Acromegaly, 2018 - 2030 (USD Million)
  • 5.5. NET
    • 5.5.1. Somatostatin Analogs Market, in NET, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Somatostatin Analogs Market, in Others, 2018 - 2030 (USD Million)

Chapter 6. Somatostatin Analogs Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Segment Market, 2018 - 2030 (USD Million)
  • 6.5. Clinics
    • 6.5.1. Clinics Segment Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Segment Market, 2018 - 2030 (USD Million)

Chapter 7. Somatostatin Analogs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.10. Russia
      • 7.5.10.1. Key Country Dynamics
      • 7.5.10.2. Regulatory Framework
      • 7.5.10.3. Competitive Insights
      • 7.5.10.4. Russia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. India Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. South Korea Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Hong Kong
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. Hong Kong Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Singapore
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Singapore Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.8. Japan
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Regulatory Framework
      • 7.6.8.3. Competitive Insights
      • 7.6.8.4. Japan Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.9. Thailand
      • 7.6.9.1. Key Country Dynamics
      • 7.6.9.2. Regulatory Framework
      • 7.6.9.3. Competitive Insights
      • 7.6.9.4. Thailand Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East & Africa
    • 7.8.1. Middle East & Africa Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. Kuwait
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. Kuwait Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. South Africa
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. South Africa Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. UAE
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. UAE Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Novo Nordisk A/S
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Eli Lilly and Company
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Medical Device Business Services, Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Johnson & Johnson Services, Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Stryker
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Ultragenyx Pharmaceutical Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Alexion Pharmaceuticals, Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Type Benchmarking
      • 8.5.8.4. Strategic Initiatives